Should you trust healthcare AI? Learn about safe development and deployment practices, and the future of AI regulation in healthcare.
Read Article
What you need to know about GLP-1s, and how Omada can help
Learn MoreOmada Health presented three posters at the Society of Behavioral Medicine's Annual Meeting. New data demonstrates behavioral, mental, and physical health benefits of Omada's cardiometabolic programs.
Read Article
Omada’s Clinical Advisory Board demonstrates its commitment to rigorous clinical evaluation and helps underscore the impact of its behavior change programs
Read Article
This analysis showed that across diverse sociodemographic populations, Omada cardiometabolic members experienced improvements in depression and anxiety symptoms.
Read Article
This analysis found that providing Omada members the opportunity to make a guided decision about curriculum theme resulted in greater engagement compared to receiving content in a standardized order
Read Article
Real-world data analysis shows Omada members, on average, experienced virtually no weight gain 16 weeks after discontinuing a GLP-1 compared to an average of 6-7% weight gain estimated from trial data
Read Article
As the healthcare industry innovates to maximize the GLP-1 experience for patients, there appears to be an important factor that’s arguably under-discussed: loneliness.
Read Article
Omada Insights Lab surveyed and interviewed Omada members with a history of GLP-1 use to learn more about their unique needs and experiences.
Read Resource
Survey finds only 18% of respondents who discontinued GLP-1s achieved their weight loss goals; respondents want to lose an average of 22% more weight.
Read Article
Cardiovascular disease (CVD) remains the leading cause of death among women, yet it is often misdiagnosed and/or undertreated. Join the discussion on the need for more focus on women's heart health.
Watch Video
New consumer data indicates that sustaining weight loss and overall well-being requires intervention beyond the GLP-1
Read Resource
Return on Health Framework for Realizing the Value of Virtual Care
Read Resource
Dr. Beal brings extensive experience in clinical innovation, patient advocacy, and population health to Omada’s Board.
Read Article
This insightful webinar delves into the expanding role of GLP-1 medications in treating a wide range of chronic conditions beyond diabetes and obesity.
Watch Video
New board members provide deep clinical and commercial experience.
Read Article
Medicare Advantage members thrive with virtual care. Contrary to popular belief, older adults engage with Omada Health chronic care management programs more than younger populations.
Read Resource
What you need to know about GLP-1s, and how Omada can help
Learn MoreWith the emergence of GLP-1s, there is a divide between patient perception of the medication and how clinical science views it. Find out more with Omada.
Read Article
Clinical and cultural conversations around obesity have long revolved around BMI (and its credibility), harmful stereotypes, issues of equity and the multi-million dollar weight loss industry.
Read Resource
A side-effect of taking GLP-1s is a loss of muscle mass. Julie Mulcahy, PT, DPT, CAPP OB explores how to combat this with resistance exercises.
Read Article
Lisa McCormick, FNP-BC, RD, CDCES explores the science behind dieting and why it doesn't work. Find out more about sustainable weight loss!
Read Article
Loading More...
